La Jolla Pharmaceutical Company (NASDAQ:LJPC)
Industry: Healthcare

OFF LIST - 792 consecutive market days: OFF LIST as of 04/12/2013 Through 11/14/2016

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock. It is also developing LJPC-0118 for the treatment of severe malaria; and LJPC-401 (synthetic human hepcidin), a clinical-stage investigational product to treat conditions characterized by iron overload, including hereditary hemochromatosis, beta thalassemia, sickle cell disease, myelodysplastic syndrome, and polycythemia vera. The company was founded in 1989 and is headquartered in San Diego, California.

Current Quote*
Last: $10.010
Change: -0.260
Book: $Unk
Volume: 169,573

As Of: 09/20 12:20 ET
*Quotes delayed by 20min.

Graphs for LJPC


3 Month Graph


6 Month Graph


1 Year Graph